RegenVOX: a Phase I/II clinical trial of stem cell-based tissue-engineered laryngeal implants
Martin Birchall(University of Bristol), Mark W. Lowdell(Royal Free London NHS Foundation Trust), Gurpreet Sandhu(Royal National Throat Nose and Ear Hospital), Alexander M. Seifalian(University of London), Emily J Culme-Seymour(GlaxoSmithKline (United Kingdom)), Rinat Ezra(University College London), Jeff Round(University College London), Sam M. Janes(University College London), Susan Tebbs(MRC Clinical Trials Unit at UCL), Anne GM Schilder(University College London), Carla Carvalho(The Royal Free Hospital), Rose Sheridan(University College London), Chris Mason(Oak Ridge National Laboratory), Tahera Ansari(Northwick Park Hospital)
Cited by 1
Related Papers
Single-cell multi-omics analysis of the immune response in COVID-19
|Nature Medicine|2021|826
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
BTRFS
|ACM Transactions on Storage|2013|381
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276